vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与WORLD ACCEPTANCE CORP（WRLD）财务数据对比。点击上方公司名可切换其他公司
WORLD ACCEPTANCE CORP的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.9倍（$141.3M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 1.9%），WORLD ACCEPTANCE CORP自由现金流更多（$57.2M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -5.8%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
本公司是一家汽车金融企业，主营汽车贷款及相关金融产品，业务通过全国合作经销商网络开展。目前公司运营两大核心业务项目，分别为投资组合项目与收购项目，通过这两个项目，公司可向汽车经销商预先提供资金，以此获得底层消费贷款的服务权等相关权益。
PBYI vs WRLD — 直观对比
营收规模更大
WRLD
是对方的1.9倍
$75.5M
营收增速更快
PBYI
高出25.8%
1.9%
自由现金流更多
WRLD
多$42.8M
$14.4M
两年增速更快
PBYI
近两年复合增速
-5.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $141.3M |
| 净利润 | — | $-911.3K |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | -0.7% |
| 净利率 | — | -0.6% |
| 营收同比 | 27.7% | 1.9% |
| 净利润同比 | — | -106.8% |
| 每股收益（稀释后） | $0.26 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIWRLD
| Q4 25 | $75.5M | $141.3M | ||
| Q3 25 | $54.5M | $134.5M | ||
| Q2 25 | $52.4M | $132.5M | ||
| Q1 25 | $46.0M | $165.3M | ||
| Q4 24 | $59.1M | $138.6M | ||
| Q3 24 | $80.5M | $131.4M | ||
| Q2 24 | $47.1M | $129.5M | ||
| Q1 24 | $43.8M | $159.3M |
净利润PBYIWRLD
| Q4 25 | — | $-911.3K | ||
| Q3 25 | $8.8M | $-1.9M | ||
| Q2 25 | $5.9M | $1.3M | ||
| Q1 25 | $3.0M | $44.3M | ||
| Q4 24 | — | $13.4M | ||
| Q3 24 | $20.3M | $22.1M | ||
| Q2 24 | $-4.5M | $9.9M | ||
| Q1 24 | $-4.8M | $35.1M |
毛利率PBYIWRLD
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIWRLD
| Q4 25 | 22.7% | -0.7% | ||
| Q3 25 | 17.6% | -1.3% | ||
| Q2 25 | 12.7% | 1.5% | ||
| Q1 25 | 8.7% | 33.3% | ||
| Q4 24 | 22.6% | 11.6% | ||
| Q3 24 | 27.4% | 21.3% | ||
| Q2 24 | -4.6% | 10.0% | ||
| Q1 24 | -5.3% | 29.3% |
净利率PBYIWRLD
| Q4 25 | — | -0.6% | ||
| Q3 25 | 16.2% | -1.4% | ||
| Q2 25 | 11.2% | 1.0% | ||
| Q1 25 | 6.5% | 26.8% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | 25.2% | 16.8% | ||
| Q2 24 | -9.6% | 7.7% | ||
| Q1 24 | -11.0% | 22.0% |
每股收益（稀释后）PBYIWRLD
| Q4 25 | $0.26 | $-0.19 | ||
| Q3 25 | $0.17 | $-0.38 | ||
| Q2 25 | $0.12 | $0.25 | ||
| Q1 25 | $0.06 | $8.07 | ||
| Q4 24 | $0.40 | $2.45 | ||
| Q3 24 | $0.41 | $3.99 | ||
| Q2 24 | $-0.09 | $1.79 | ||
| Q1 24 | $-0.10 | $6.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $10.0M |
| 总债务越低越好 | $22.7M | $677.2M |
| 股东权益账面价值 | $130.3M | $351.6M |
| 总资产 | $216.3M | $1.1B |
| 负债/权益比越低杠杆越低 | 0.17× | 1.93× |
8季度趋势，按日历期对齐
现金及短期投资PBYIWRLD
| Q4 25 | $97.5M | $10.0M | ||
| Q3 25 | $94.4M | $14.9M | ||
| Q2 25 | $96.0M | $8.1M | ||
| Q1 25 | $93.2M | $4.7M | ||
| Q4 24 | $101.0M | $10.3M | ||
| Q3 24 | $96.7M | $9.7M | ||
| Q2 24 | $96.8M | $11.1M | ||
| Q1 24 | $107.2M | $5.2M |
总债务PBYIWRLD
| Q4 25 | $22.7M | $677.2M | ||
| Q3 25 | $34.0M | $584.6M | ||
| Q2 25 | $45.3M | $472.5M | ||
| Q1 25 | $56.7M | $447.9M | ||
| Q4 24 | $68.0M | $561.2M | ||
| Q3 24 | $79.3M | $506.6M | ||
| Q2 24 | $90.7M | $494.7M | ||
| Q1 24 | $102.0M | $498.4M |
股东权益PBYIWRLD
| Q4 25 | $130.3M | $351.6M | ||
| Q3 25 | $115.3M | $365.6M | ||
| Q2 25 | $104.7M | $427.9M | ||
| Q1 25 | $97.1M | $439.5M | ||
| Q4 24 | $92.1M | $428.2M | ||
| Q3 24 | $71.1M | $417.5M | ||
| Q2 24 | $48.5M | $422.6M | ||
| Q1 24 | $51.0M | $424.4M |
总资产PBYIWRLD
| Q4 25 | $216.3M | $1.1B | ||
| Q3 25 | $202.9M | $1.1B | ||
| Q2 25 | $194.9M | $1.0B | ||
| Q1 25 | $196.2M | $1.0B | ||
| Q4 24 | $213.3M | $1.1B | ||
| Q3 24 | $220.7M | $1.0B | ||
| Q2 24 | $205.0M | $1.0B | ||
| Q1 24 | $214.1M | $1.1B |
负债/权益比PBYIWRLD
| Q4 25 | 0.17× | 1.93× | ||
| Q3 25 | 0.30× | 1.60× | ||
| Q2 25 | 0.43× | 1.10× | ||
| Q1 25 | 0.58× | 1.02× | ||
| Q4 24 | 0.74× | 1.31× | ||
| Q3 24 | 1.12× | 1.21× | ||
| Q2 24 | 1.87× | 1.17× | ||
| Q1 24 | 2.00× | 1.17× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $58.0M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $57.2M |
| 自由现金流率自由现金流/营收 | 19.1% | 40.5% |
| 资本支出强度资本支出/营收 | 0.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | $412.5M |
8季度趋势，按日历期对齐
经营现金流PBYIWRLD
| Q4 25 | $14.4M | $58.0M | ||
| Q3 25 | $9.7M | $48.6M | ||
| Q2 25 | $14.1M | $58.2M | ||
| Q1 25 | $3.6M | $254.2M | ||
| Q4 24 | $15.6M | $61.1M | ||
| Q3 24 | $11.0M | $53.8M | ||
| Q2 24 | $1.0M | $48.4M | ||
| Q1 24 | $11.2M | $265.8M |
自由现金流PBYIWRLD
| Q4 25 | $14.4M | $57.2M | ||
| Q3 25 | $9.7M | $47.7M | ||
| Q2 25 | $14.1M | $57.1M | ||
| Q1 25 | $3.6M | $250.5M | ||
| Q4 24 | $15.6M | $60.4M | ||
| Q3 24 | $11.0M | $52.7M | ||
| Q2 24 | $1.0M | $47.3M | ||
| Q1 24 | — | $259.9M |
自由现金流率PBYIWRLD
| Q4 25 | 19.1% | 40.5% | ||
| Q3 25 | 17.7% | 35.5% | ||
| Q2 25 | 26.8% | 43.1% | ||
| Q1 25 | 7.7% | 151.6% | ||
| Q4 24 | 26.4% | 43.6% | ||
| Q3 24 | 13.7% | 40.1% | ||
| Q2 24 | 2.1% | 36.5% | ||
| Q1 24 | — | 163.2% |
资本支出强度PBYIWRLD
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 0.8% | ||
| Q1 24 | 0.0% | 3.7% |
现金转化率PBYIWRLD
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | 43.27× | ||
| Q1 25 | 1.21× | 5.74× | ||
| Q4 24 | — | 4.56× | ||
| Q3 24 | 0.54× | 2.43× | ||
| Q2 24 | — | 4.87× | ||
| Q1 24 | — | 7.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
